2023/03/09 更新

写真a

イワセ マドカ
岩瀬 まどか
IWASE Madoka
所属
医学部附属病院 乳腺・内分泌外科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 医学博士 ( 2021年3月   名古屋大学 ) 

 

論文 22

  1. [Ⅳ. Clinical Trials on OncotypeDX-TAILORx and JBCRG-TR003 Trial].

    Iwase M, Masuda N

    Gan to kagaku ryoho. Cancer & chemotherapy   49 巻 ( 12 ) 頁: 1324 - 1327   2022年12月

     詳細を見る

    記述言語:日本語  

    PubMed

  2. A novel information sharing system via YouTube to provide breast cancer information and to raise public breast awareness

    Iesato Asumi, Terada Mitsuo, Fushimi Atsushi, Tahara Rie, Nishiyama Kanako, Iwase Madoka, Yamashita Nami

    ANNALS OF ONCOLOGY   33 巻   頁: S492 - S492   2022年7月

  3. Association between germline pathogenic variants and breast cancer risk in Japanese women: The HERPACC study

    Kasugai Yumiko, Kohmoto Tomohiro, Taniyama Yukari, Koyanagi Yuriko N., Usui Yoshiaki, Iwase Madoka, Oze Isao, Yamaguchi Rui, Ito Hidemi, Imoto Issei, Matsuo Keitaro

    CANCER SCIENCE   113 巻 ( 4 ) 頁: 1451 - 1462   2022年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Approximately 5%–10% of breast cancers are hereditary, caused by germline pathogenic variants (GPVs) in breast cancer predisposition genes. To date, most studies of the prevalence of GPVs and risk of breast cancer for each gene based on cases and noncancer controls have been conducted in Europe and the United States, and little information from Japanese populations is available. Furthermore, no studies considered confounding by established environmental factors and single-nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) together in GPV evaluation. To evaluate the association between GPVs in nine established breast cancer predisposition genes including BRCA1/2 and breast cancer risk in Japanese women comprehensively, we conducted a case-control study within the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (629 cases and 1153 controls). The associations between GPVs and the risk of breast cancer were assessed by odds ratios (OR) and 95% confidence intervals (CI) using logistic regression models adjusted for potential confounders. A total of 25 GPVs were detected among all cases (4.0%: 95% CI: 2.6–5.9), whereas four individuals carried GPVs in all controls (0.4%). The OR for breast cancer by all GPVs and by GPVs in BRCA1/2 was 12.2 (4.4–34.0, p = 1.74E-06) and 16.0 (4.2–60.9, p = 5.03E-0.5), respectively. A potential confounding with GPVs was observed for the GWAS-identified SNPs, whereas not for established environmental risk factors. In conclusion, GPVs increase the risk of breast cancer in Japanese women regardless of environmental factors and GWAS-identified SNPs. Future studies investigating interactions with environment and SNPs are warranted.

    DOI: 10.1111/cas.15312

    Web of Science

    Scopus

    PubMed

  4. Differences in baseline risk estimated by physicians and patients with early breast cancer

    Mori M., Yoshimura A., Sawaki M., Hattori M., Kotani H., Adachi Y., Iwase M., Kataoka A., Sugino K., Horisawa N., Ozaki Y., Iwata H., Onishi S., Gondo N., Terada M.

    Japanese Journal of Clinical Oncology   51 巻 ( 12 ) 頁: 1703 - 1707   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:Japanese Journal of Clinical Oncology  

    Background: Physicians recommend adjuvant therapy to patients based on baseline risk. A common recognition for baseline risk between patients and physicians is critical for successful adjuvant therapy. We prospectively investigated the differences in estimated baseline risk between physicians and patients with early breast cancer. Methods: This analysis was performed at a single institution in Japan. Early breast cancer patients over 18 years old were enrolled after surgery. After explaining the pathological results, physicians asked each patient about an estimated baseline risk. Differences in estimated baseline risk were defined as the baseline risk estimated by patients minus the baseline risk estimated by physicians. The primary endpoint was that the number of patients who estimate baseline risk higher than physicians was higher than those who estimate a lower baseline risk. The secondary endpoints were differences in estimated baseline risk by stage, subtype and the influence of patient factors to differences in estimated baseline risk. Results: From July 2017 to December 2018, 262 patients were enrolled. Among the 262 patients, 190 estimated a higher baseline risk than physicians, 53 estimated a lower baseline risk and 19 estimated the same. Overall, patients estimated a significantly higher baseline risk than physicians (P < 0.001). Differences in estimated baseline risk was significantly smaller in patients who knew the term 'baseline risk' than patients who did not (P = 0.0037). Differences in estimated baseline risk were also significantly smaller in patients with stage II breast cancer than patients with stage I (P = 0.0239). However, there were no statistically significant differences of differences in estimated baseline risk according to other factors. Conclusions: Patients with early breast cancer estimated a significantly higher baseline risk than physicians. Physicians should accurately explain baseline risk to patients for shared decision making.

    DOI: 10.1093/jjco/hyab152

    Scopus

    PubMed

  5. Circular stapled technique versus modified Collard technique for cervical esophagogastric anastomosis after esophagectomy: A randomized controlled trial.

    Hosoi T, Abe T, Higaki E, Fujieda H, Nagao T, Ito S, Komori K, Iwase M, Oze I, Shimizu Y

    Annals of surgery     2021年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1097/SLA.0000000000005185

    PubMed

  6. Alcohol consumption and breast cancer risk in Japan: A pooled analysis of eight population-based cohort studies 査読有り

    Iwase Madoka, Matsuo Keitaro, Koyanagi Yuriko N. Y., Ito Hidemi, Tamakoshi Akiko, Wang Chaochen, Utada Mai, Ozasa Kotaro, Sugawara Yumi, Tsuji Ichiro, Sawada Norie, Tanaka Shiori, Nagata Chisato, Kitamura Yuri, Shimazu Taichi, Mizoue Tetsuya, Naito Mariko, Tanaka Keitaro, Inoue Manami

    INTERNATIONAL JOURNAL OF CANCER   148 巻 ( 11 ) 頁: 2736 - 2747   2021年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:International Journal of Cancer  

    Although alcohol consumption is reported to increase the incidence of breast cancer in European studies, evidence for an association between alcohol and breast cancer in Asian populations is insufficient. We conducted a pooled analysis of eight large-scale population-based prospective cohort studies in Japan to evaluate the association between alcohol (both frequency and amount) and breast cancer risk with categorization by menopausal status at baseline and at diagnosis. Estimated hazard ratios (HR) and 95% confidence intervals were calculated in the individual cohorts and combined using random-effects models. Among 158 164 subjects with 2 369 252 person-years of follow-up, 2208 breast cancer cases were newly diagnosed. Alcohol consumption had a significant association with a higher risk of breast cancer in both women who were premenopausal at baseline (regular drinker compared to nondrinker: HR 1.37, 1.04-1.81, ≥23 g/d compared to 0 g/d: HR 1.74, 1.25-2.43, P for trend per frequency category: P =.017) and those who were premenopausal at diagnosis (≥23 g/d compared to 0 g/d: HR 1.89, 1.04-3.43, P for trend per frequency category: P =.032). In contrast, no significant association was seen in women who were postmenopausal at baseline or at diagnosis, despite a substantial number of subjects and long follow-up period. Our results revealed that frequent and high alcohol consumption are both risk factors for Asian premenopausal breast cancer, similarly to previous studies in Western countries. The lack of a clear association in postmenopausal women in our study warrants larger investigation in Asia.

    DOI: 10.1002/ijc.33478

    Web of Science

    Scopus

    PubMed

  7. Differential Effect of Polymorphisms on Body Mass Index Across the Life Course of Japanese: The Japan Multi-Institutional Collaborative Cohort Study

    Iwase Madoka, Matsuo Keitaro, Nakatochi Masahiro, Oze Isao, Ito Hidemi, Koyanagi Yuriko, Ugai Tomotaka, Kasugai Yumiko, Hishida Asahi, Takeuchi Kenji, Okada Rieko, Kubo Yoko, Shimanoe Chisato, Tanaka Keitaro, Ikezaki Hiroaki, Murata Masayuki, Takezaki Toshiro, Nishimoto Daisaku, Kuriyama Nagato, Ozaki Etsuko, Suzuki Sadao, Watanabe Miki, Mikami Haruo, Nakamura Yohko, Uemura Hirokazu, Katsuura-Kamano Sakurako, Kuriki Kiyonori, Kita Yoshikuni, Naoyuki Takashima, Nagino Masato, Momozawa Yukihide, Kubo Michiaki, Wakai Kenji

    Journal of Epidemiology   31 巻 ( 3 ) 頁: 172 - 179   2021年3月

     詳細を見る

    記述言語:英語   出版者・発行元:日本疫学会  

    Background: Obesity is a reported risk factor for various health problems. Genome-wide association studies (GWASs) have identified numerous independent loci associated with body mass index (BMI). However, most of these have been focused on Europeans, and little evidence is available on the genetic effects across the life course of other ethnicities. Methods: We conducted a cross-sectional study to examine the associations of 282 GWAS-identified single nucleotide polymorphisms with three BMI-related traits, current BMI, BMI at 20 years old (BMI at 20), and change in BMI (BMI change), among 11,586 Japanese individuals enrolled in the Japan Multi-Institutional Collaborative Cohort study. Associations were examined using multivariable linear regression models. Results: We found a significant association (P < 0.05=282 = 1.77 × 10−4) between BMI and 11 polymorphisms in or near FTO, BDNF, TMEM18, HS6ST3, and BORCS7. The trend was similar between current BMI and BMI change, but differed from that of the BMI at 20. Among the significant variants, those on FTO were associated with all BMI traits, whereas those on TMEM18 and HS6SR3 were only associated with BMI at 20. The association of FTO loci with BMI remained, even after additional adjustment for dietary energy intake. Conclusions: Previously reported BMI-associated loci discovered in Europeans were also identified in the Japanese population. Additionally, our results suggest that the effects of each loci on BMI may vary across the life course and that this variation may be caused by the differential effects of individual genes on BMI via different pathways.

    DOI: 10.2188/jea.je20190296

    Web of Science

    Scopus

    PubMed

    CiNii Research

  8. Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction.

    Adachi Y, Okumura S, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Iwase M, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Endo Y, Sakamoto S, Iwata H

    Breast cancer (Tokyo, Japan)   27 巻 ( 4 ) 頁: 716 - 723   2020年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s12282-020-01065-4

    PubMed

  9. Across-Site Differences in the Mechanism of Alcohol-Induced Digestive Tract Carcinogenesis: An Evaluation by Mediation Analysis

    Koyanagi Yuriko N., Suzuki Etsuji, Imoto Issei, Kasugai Yumiko, Oze Isao, Ugai Tomotaka, Iwase Madoka, Usui Yoshiaki, Kawakatsu Yukino, Sawabe Michi, Hirayama Yutaka, Tanaka Tsutomu, Abe Tetsuya, Ito Seiji, Komori Koji, Hanai Nobuhiro, Tajika Masahiro, Shimizu Yasuhiro, Niwa Yasumasa, Ito Hidemi, Matsuo Keitaro

    CANCER RESEARCH   80 巻 ( 7 ) 頁: 1601 - 1610   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Cancer Research  

    A genetic variant on aldehyde dehydrogenase 2 (ALDH2 rs671, Glu504Lys) contributes to carcinogenesis after alcohol consumption. Somewhat conversely, the ALDH2 Lys allele also confers a protective effect against alcohol-induced carcinogenesis by decreasing alcohol consumption due to acetaldehyde-related adverse effects. Here, we applied a mediation analysis to five case–control studies for head and neck, esophageal, stomach, small intestine, and colorectal cancers, with 4,099 cases and 6,065 controls, and explored the potentially heterogeneous impact of alcohol drinking on digestive tract carcinogenesis by decomposing the total effect of the ALDH2 Lys allele on digestive tract cancer risk into the two opposing effects of the carcinogenic effect (direct effect) and the protective effect (indirect effect mediated by drinking behavior). Alcohol was associated with an increased risk of most digestive tract cancers, but significant direct effects were observed only for upper gastrointestinal tract cancer risk, and varied substantially by site, with ORs (95% confidence interval) of 1.83 (1.43–2.36) for head and neck cancer, 21.15 (9.11–49.12) for esophageal cancer, and 1.65 (1.38–1.96) for stomach cancer. In contrast, a significant protective indirect effect was observed on risk for all cancers, except small intestine cancer. These findings suggest that alcohol is a major risk factor for digestive tract cancers, but its impact as a surrogate for acetaldehyde exposure appears heterogeneous by site. Meanwhile, the behavior-related effect of the ALDH2 Lys allele results in a decreased risk of most digestive tract cancers.

    DOI: 10.1158/0008-5472.CAN-19-2685

    Web of Science

    Scopus

    PubMed

  10. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer 査読有り

    Iwase Madoka, Ando Masashi, Aogi Kenjiro, Aruga Tomoyuki, Inoue Kenichiro, Shimomura Akihiko, Tokunaga Eriko, Masuda Norikazu, Yamauchi Hideko, Yamashita Toshinari, Iwata Hiroji

    BREAST CANCER RESEARCH AND TREATMENT   180 巻 ( 3 ) 頁: 687 - 694   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Breast Cancer Research and Treatment  

    Purpose: Addition of carboplatin (CBDCA) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) has improved pathological complete response (pCR) rates in previous studies. We present long-term survival outcomes (disease-free survival [DFS], pre-planned secondary endpoint; overall survival [OS], post hoc exploratory endpoint) of our randomized study of the addition of CBDCA to NAC for HER2-negative breast cancer. Methods: Patients with stage II/III, HER2-negative breast cancer (N = 179) were randomly assigned to receive CP–CEF (four 3-week cycles of CBDCA [area under the curve, 5 mg/mL/min, day 1] and weekly paclitaxel [wPTX, 80 mg/m2, day 1, 8, 15] followed by four 3-week cycles of cyclophosphamide, epirubicin, and 5-fluorouracil [CEF, 500/100/500 mg/m2]) or P–CEF (four cycles of wPTX followed by four cycles of CEF) as NAC. DFS and OS were analyzed at each population of pCR status and assigned treatment arm. Results: Of 179 patients, 154 were available for long-term follow-up. At a median follow-up of 6.6 years (range, 0.7–8.0 years), patients who achieved pCR [n = 42, 23.5% (CP–CEF: n = 28, P–CEF: n = 16)] had longer DFS and OS than non-pCR patients [DFS; HR 0.15 (0.04–0.61), P = 0.008, OS; log-rank P = 0.003]. Addition of carboplatin to NAC significantly improved DFS and OS in the subset of patients with TNBC [DFS: HR, 0.22 (0.06–0.82), P = 0.015; OS: HR, 0.12 (0.01–0.96), P = 0.046], but not in the subset of patients with hormone receptor-positive disease or among all patients. Conclusions: Addition of carboplatin to neoadjuvant chemotherapy significantly improved DFS and OS in patients with TNBC but not in those with hormone receptor-positive, HER2-negative breast cancer.

    DOI: 10.1007/s10549-020-05580-y

    Web of Science

    Scopus

    PubMed

  11. Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors

    Terada M., Yoshimura A., Sawaki M., Hattori M., Naomi G., Kotani H., Adachi Y., Iwase M., Kataoka A., Sugino K., Mori M., Horisawa N., Ozaki Y., Iwata H.

    Breast Cancer Research and Treatment   179 巻 ( 1 ) 頁: 91 - 100   2020年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:Breast Cancer Research and Treatment  

    Purpose: Lymphedema (LE) decreases the quality of life of breast cancer patients. Objective quantification of PRO may improve the discordance between patient-reported outcomes (PROs) and objective assessments of LE by establishing a standard follow-up for LE. This study determined the prevalence of subjective and objective LE and evaluated the correlation between objective assessment and PRO of LE in primary breast cancer patients undergoing breast and axilla surgery. Methods: Breast cancer patients who underwent sentinel lymph node biopsy (SN) or axillary lymph node dissection (ALND) more than 1 year after surgery were enrolled. We prospectively evaluated LE using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and two objective assessments (arm circumference and bioimpedance) and analyzed their correlations. Results: Between November 2018 and January 2019, 631 patients (SN; n = 415, ALND; n = 216) were enrolled. The median age, body mass index, and duration from surgery was 56 years, 21.9 kg/m2, and 3.8 years, respectively. The prevalences of subjective and objective LE were 4.1% and 1.4% in the SN group and 51.8% and 24.1% in the ALND group, respectively. The objective assessments were weakly positively correlated with PRO-CTCAE. Arm circumference measurement correlated better than bioimpedance overall and was most strongly correlated with “frequency” (r = 0.485, p < 0.01). Conclusions: LE occurred in few SN patients. The prevalence of subjective LE was higher than that of objective LE. Arm circumference measurements better reflected PRO than did bioimpedance. These results underscore the limitation of LE detection by subjective or objective methods alone.

    DOI: 10.1007/s10549-019-05443-1

    Scopus

    PubMed

  12. Circulating tumor cells detection in tumor draining vein of breast cancer patients.

    Hattori M, Nakanishi H, Yoshimura M, Iwase M, Yoshimura A, Adachi Y, Gondo N, Kotani H, Sawaki M, Fujita N, Yatabe Y, Iwata H

    Scientific reports   9 巻 ( 1 ) 頁: 18195   2019年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1038/s41598-019-54839-y

    PubMed

  13. Presence of small residual malignant lesions in pathologic complete response after neo-adjuvant chemotherapy in patients with breast cancer. 査読有り

    Iwase M, Hattori M, Sawaki M, Yoshimura A, Kotani H, Gondo N, Adachi Y, Kataoka A, Onishi S, Sugino K, Horisawa N, Mori M, Terada M, Iwata H

    The breast journal   25 巻 ( 6 ) 頁: 1303 - 1305   2019年11月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/tbj.13473

    PubMed

  14. The overall survival of breast cancer patients without adjuvant therapy.

    Onishi S, Sawaki M, Ishiguro J, Kataoka A, Iwase M, Sugino K, Adachi Y, Gondo N, Kotani H, Yoshimura A, Hattori M, Matsuo K, Yatabe Y, Iwata H

    Surgery today   49 巻 ( 7 ) 頁: 610 - 620   2019年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s00595-019-01775-z

    PubMed

  15. A case of giant cell tumor of the breast, clinically suspected as malignant breast tumor.

    Terada M, Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, Iwase M, Kataoka A, Sugino K, Mori M, Horisawa N, Ozaki Y, Iwata H

    Surgical case reports   5 巻 ( 1 ) 頁: 77   2019年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1186/s40792-019-0635-4

    PubMed

  16. Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy

    Kataoka A., Sawaki M., Okumura S., Onishi S., Iwase M., Sugino K., Ishiguro J., Gondo N., Kotani H., Yoshimura A., Hattori M., Sasaki E., Yatabe Y., Yoshimura K., Omi K., Iwata H.

    Breast Journal   25 巻 ( 2 ) 頁: 202 - 206   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:Breast Journal  

    Skin-sparing mastectomy (SSM) with immediate reconstruction is standard surgical treatment for early breast cancer with widespread ductal carcinoma in situ (DCIS). The local recurrence rate after SSM is up to 7.0%. We investigated prediction of the pathological margin using contrast-enhanced MRI, and evaluated the cut-off point to obtain the safety margin. We performed SSM with immediate reconstruction in 216 early breast cancer patients with widespread DCIS and/or invasive cancer from January 2014 to December 2015. Forty cases were retrospectively reviewed after excluding those with >15 mm between skin and tumor, determined by preoperative contrast-enhanced MRI, or involving reconstructive surgery for local recurrence, immeasurable lesion by preoperative contrast-enhanced MRI, or neoadjuvant chemotherapy. We defined a positive pathological margin as <1 mm from the cancer nest. We reviewed the distance between skin and tumor by MRI and pathological examination. To identify the cut-off for predicting a positive pathological margin, we performed sensitivity analysis using an ROC curve. The margin-positive rate by pathological examination was 27.5% (n = 11/40), with a moderate correlation of MRI margin and pathological margin (r = 0.44). The best cut-off point for margin positivity was 5 mm of MRI margin, with sensitivity and specificity of 54% and 86%, respectively (P = 0.009). This is the first prediction of pathological margin by preoperative contrast-enhanced MRI in early breast cancer patients with SSM. Care is required for SSM if the MRI margin is less than 5 mm due to pathological margin positivity.

    DOI: 10.1111/tbj.13194

    Scopus

    PubMed

  17. Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.

    Terada M, Adachi Y, Sawaki M, Hattori M, Yoshimura A, Naomi G, Kotani H, Iwase M, Kataoka A, Onishi S, Sugino K, Mori M, Horisawa N, Sasaki E, Yatabe Y, Iwata H

    Breast cancer research and treatment   172 巻 ( 1 ) 頁: 1 - 7   2018年11月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s10549-018-4898-4

    PubMed

  18. Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery. 査読有り

    Breast Cancer   25 巻 ( 5 ) 頁: 583 - 589   2018年9月

     詳細を見る

    担当区分:筆頭著者  

    DOI: 10.1007/s12282-018-0856-6

  19. Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma.

    Adachi Y, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Iwase M, Kataoka A, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Oze I, Iwata H

    Breast cancer (Tokyo, Japan)   25 巻 ( 5 ) 頁: 560 - 565   2018年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s12282-018-0852-x

    PubMed

  20. Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.

    Yoshimura A, Okumura S, Sawaki M, Hattori M, Ishiguro J, Adachi Y, Kotani H, Gondo N, Kataoka A, Iwase M, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Takaiso N, Hyodo I, Iwata H

    Breast cancer (Tokyo, Japan)   25 巻 ( 5 ) 頁: 539 - 546   2018年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s12282-018-0850-z

    PubMed

  21. The investigation study using a questionnaire about the employment of Japanese breast cancer patients.

    Kotani H, Kataoka A, Sugino K, Iwase M, Onishi S, Adachi Y, Gondo N, Yoshimura A, Hattori M, Sawaki M, Iwata H

    Japanese journal of clinical oncology   48 巻 ( 8 ) 頁: 712 - 717   2018年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/jjco/hyy088

    PubMed

  22. Overcalling low-risk findings: grouped amorphous calcifications found at screening mammography associated with minimal cancer risk. 査読有り

    Iwase M, Tsunoda H, Nakayama K, Morishita E, Hayashi N, Suzuki K, Yamauchi H

    Breast cancer (Tokyo, Japan)   24 巻 ( 4 ) 頁: 579 - 584   2017年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s12282-016-0742-z

    PubMed

▼全件表示

講演・口頭発表等 2

  1. ディベートセッション:ホルモン陽性HER2陰性の術後治療に関して

    齋藤亜由美 /日比野幸子 / 能澤一樹 /岩瀬まどか

    第30回日本乳癌学会総会  2022年6月30日  日本乳癌学会

     詳細を見る

    開催年月日: 2022年6月 - 2022年7月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:横浜   国名:日本国  

  2. 保険診療下でのリスク低減手術の現状と課題

    岩瀬まどか 高野悠子 森川真紀 菊森豊根 角田伸行 武内大 柴田雅央 稲石貴弘 添田郁美 一川貴洋 杉野香世子 増田慎三

    第30回日本乳癌学会総会  日本乳癌学会

     詳細を見る

    開催年月日: 2022年6月 - 2022年7月

    記述言語:日本語   会議種別:ポスター発表  

    国名:日本国